The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Nivadil     propan-2-yl methyl 2-cyano-6-methyl-4-(3...

Synonyms: Nivadipine, Escor, Nilvadipino, nilvadipine, Nilvadipinum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Nivadil

  • The mechanism of the antianginal actions of nilvadipine was investigated in 11 patients with effort angina pectoris [1].
  • Compared with chest pain during control exercise testing, pain at peak exercise disappeared or abated and the ST segment at peak exercise also showed less significant depression after administration of nilvadipine [1].
  • Thus, nilvadipine might prevent cerebral vascular disorders at doses routinely used for essential hypertension [2].
  • We investigated the effects of nilvadipine, a calcium antagonist, on cerebral ischemia in rats [3].
  • By densitometric quantification of the electrophoretically separated soluble proteins, mean +/- SEM MAP2 content in the hippocampus (14.4 +/- 1.8 micrograms/mg protein) was depleted (5.4 +/- 0.5 micrograms/mg, p less than 0.01) 4 days after ischemia; this depletion was significantly inhibited by 1 or 10 mg nilvadipine/kg/day [4].

Psychiatry related information on Nivadil

  • The total scores of the Brief Psychiatric Rating Scale decreased significantly when the patients were on nilvadipine compared with placebo [5].
  • We investigated the effects of the Ca(2+) antagonist nilvadipine on the dopaminergic system and motor activity in aged mice, in comparison with an other Ca(2+) antagonist, amlodipine [6].
  • The total binding affinity (nK) between LDL and verapamil enantiomers was increased by 3.3-, 4.6-, 7.0-, and 19-fold after 0.5, 1, 2, and 12 h oxidation, respectively, whereas the nK value between nilvadipine and LDLwas increased by 1.3-, 1.4-, 1.4-, and 1.7-fold in the same reaction times, respectively [7].
  • The BP decreased in the HCT/T group (n = 124) compared to the nilvadipine group to a similar degree (p = 0.91, n.s.) from 160/103 +/- 17/8 mm Hg by -17/-13 +/- 18/11 mm Hg [8].
  • Nilvadipine may have a neuroprotective effect and could be a useful pharmacotherapeutic agent for cerebrovascular dementia [9].

High impact information on Nivadil


Chemical compound and disease context of Nivadil


Biological context of Nivadil


Anatomical context of Nivadil


Associations of Nivadil with other chemical compounds

  • The effects of systemic administration of 1 micro g/kg per hour nilvadipine (a calcium antagonist), 30 mg/kg N(omega)-nitro-L-arginine (L-NAME), or 5 mg/kg indomethacin, or those of sympathetic nerve amputation on the time course of the changes in NB were studied [23].
  • By optimizing chromatographic conditions such as column temperature and flow rate, the baseline separation of nilvadipine enantiomers was attained with a short analysis time and with a column efficiency comparable to commercially available chiral stationary phases based on a protein, such as ovomucoid or alpha1-acid glycoprotein [24].
  • We determined the effect of nilvadipine, a dihydropyridine-type calcium channel blocker, in preventing glutamate neurotoxicity in purified retinal ganglion cells (RGCs) [25].
  • It is suggested that some types of Ca(2+) channel blockers, such as nilvadipine and nicardipine, are able to preserve photoreceptor cells in rd mouse and can potentially be used to treat some RP patients [26].
  • In addition, the application of nilvadipine significantly reduced glutamate-induced apoptosis (P<0.001) [25].

Gene context of Nivadil


Analytical, diagnostic and therapeutic context of Nivadil

  • We investigated the efficacy of nilvadipine, a calcium channel inhibitor, for psychiatric symptoms and tardive dyskinesia in 30 patients with chronic schizophrenia in a placebo-controlled double-blind crossover study [5].
  • Twenty-four hours after the occlusion, the percentage infarct volumes in nilvadipine-treated animals in groups 1-3 (21 +/- 11%, 24 +/- 11%, and 26 +/- 7%, respectively) were smaller than those in the respective control groups (36 +/- 5%, 35 +/- 3%, and 35 +/- 3%; P < 0.05) [30].
  • Nilvadipine restored cortical perfusion levels in Tg APPsw to values similar to those observed in control littermates without notably affecting the CBF of control mice [31].
  • The versatility of the HPFA method using a diol-silica column was demonstrated by developing a novel on-line HPFA-chiral HPLC system for a simple and easy determination of the unbound concentration of nilvadipine (NV) enantiomers [32].
  • In addition, we performed DNA microarray analysis both in nilvadipine treated and control retinas to understand their drug effects at molecular levels [26].


  1. Effects of a new second generation calcium channel blocker, nilvadipine (FR34235), on exercise-induced hemodynamic changes in stable angina pectoris. Yokota, M., Koide, M., Miyahara, T., Kamihara, S., Tsunekawa, A., Noda, S., Sotobata, I. J. Am. Coll. Cardiol. (1987) [Pubmed]
  2. Effect of nilvadipine on the development of neurological deficits in stroke-prone spontaneously hypertensive rats. Takakura, S., Furuichi, Y., Yamamoto, T., Ogawa, T., Satoh, H., Mori, J. Stroke (1994) [Pubmed]
  3. Attenuated neuropathology by nilvadipine after middle cerebral artery occlusion in rats. Kawamura, S., Shirasawa, M., Fukasawa, H., Yasui, N. Stroke (1991) [Pubmed]
  4. Nilvadipine attenuates ischemic degradation of gerbil brain cytoskeletal proteins. Kuwaki, T., Satoh, H., Ono, T., Shibayama, F., Yamashita, T., Nishimura, T. Stroke (1989) [Pubmed]
  5. Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off. Yamada, K., Kanba, S., Ashikari, I., Ohnishi, K., Yagi, G., Asai, M. Journal of clinical psychopharmacology. (1996) [Pubmed]
  6. Effects of Ca2+ antagonists on motor activity and the dopaminergic system in aged mice. Kurosaki, R., Akasaka, M., Michimata, M., Matsubara, M., Imai, Y., Araki, T. Neurobiol. Aging (2003) [Pubmed]
  7. Effect of oxidation of low-density lipoprotein on drug binding affinity studied by high performance frontal analysis-capillary electrophoresis. Kuroda, Y., Cao, B., Shibukawa, A., Nakagawa, T. Electrophoresis (2001) [Pubmed]
  8. Comparisons of once-daily nilvadipine with enalapril and diuretic in patients with essential hypertension. Fritschka, E. J. Cardiovasc. Pharmacol. (1992) [Pubmed]
  9. Effect of nilvadipine on the cerebral ischemia-induced impairment of spatial memory and hippocampal apoptosis in rats. Iwasaki, K., Mishima, K., Egashira, N., Al-Khatib, I.H., Ishibashi, D., Irie, K., Kobayashi, H., Egawa, T., Fujiwara, M. J. Pharmacol. Sci. (2003) [Pubmed]
  10. Time course of changes in optic nerve head circulation after acute reduction in intraocular pressure. Takayama, J., Tomidokoro, A., Tamaki, Y., Araie, M. Invest. Ophthalmol. Vis. Sci. (2005) [Pubmed]
  11. Retinal dysfunction in cancer-associated retinopathy is improved by Ca(2+) antagonist administration and dark adaptation. Ohguro, H., Ogawa, K., Maeda, T., Maruyama, I., Maeda, A., Takano, Y., Nakazawa, M. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  12. Effects of calcium channel entry blockers, nifedipine and nilvadipine, on colonic motor activity. Barone, F.C., White, R.F., Ormsbee, H.S., Wasserman, M.A. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  13. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: alterations in baroreflex sensitivity. Warltier, D.C., Zyvoloski, M.G., Gross, G.J., Brooks, H.L. J. Pharmacol. Exp. Ther. (1984) [Pubmed]
  14. Selective improvement in subendocardial perfusion distal to a flow-limiting coronary artery stenosis: effects of the new calcium channel blocking agent, FR 34235, nifedipine and diltiazem. Gross, G.J., Warltier, D.C. J. Pharmacol. Exp. Ther. (1984) [Pubmed]
  15. Beneficial effects of the dihydropyridine calcium antagonist, FR 34235, in a chronic coronary occlusion model. Warltier, D.C., Zyvoloski, M.G., Brooks, H.L., Gross, G.J. Eur. J. Pharmacol. (1982) [Pubmed]
  16. Contrasting effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on calcium transients in isolated rat cardiac myocytes. Kuramochi, T., Honda, M., Tanaka, K., Mansoor, A.M., Enomoto, K., Hashimoto, M., Morioka, S. Cardiovasc. Res. (1994) [Pubmed]
  17. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade. Warltier, D.C., Zyvoloski, M.G., Gross, G.J., Brooks, H.L. J. Pharmacol. Exp. Ther. (1984) [Pubmed]
  18. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Nomoto, A., Mutoh, S., Hagihara, H., Yamaguchi, I. Atherosclerosis (1988) [Pubmed]
  19. Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers. Terakawa, M., Tokuma, Y., Kuwahara, N., Shishido, A., Noguchi, H. Journal of clinical pharmacology. (1988) [Pubmed]
  20. Preservation of retinal morphology and functions in royal college surgeons rat by nilvadipine, a Ca(2+) antagonist. Yamazaki, H., Ohguro, H., Maeda, T., Maruyama, I., Takano, Y., Metoki, T., Nakazawa, M., Sawada, H., Dezawa, M. Invest. Ophthalmol. Vis. Sci. (2002) [Pubmed]
  21. Effects of nilvadipine, a calcium antagonist, on rabbit ocular circulation and optic nerve head circulation in NTG subjects. Tomita, K., Araie, M., Tamaki, Y., Nagahara, M., Sugiyama, T. Invest. Ophthalmol. Vis. Sci. (1999) [Pubmed]
  22. Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery. Nomoto, A., Hirosumi, J., Sekiguchi, C., Mutoh, S., Yamaguchi, I., Aoki, H. Atherosclerosis (1987) [Pubmed]
  23. Time course of the change in optic nerve head circulation after an acute increase in intraocular pressure. Takayama, J., Tomidokoro, A., Ishii, K., Tamaki, Y., Fukaya, Y., Hosokawa, T., Araie, M. Invest. Ophthalmol. Vis. Sci. (2003) [Pubmed]
  24. Uniformly sized molecularly imprinted polymer for (S)-nilvadipine. Comparison of chiral recognition ability with HPLC chiral stationary phases based on a protein. Fu, Q., Sanbe, H., Kagawa, C., Kunimoto, K.K., Hagina, J. Anal. Chem. (2003) [Pubmed]
  25. Protective effect of nilvadipine against glutamate neurotoxicity in purified retinal ganglion cells. Otori, Y., Kusaka, S., Kawasaki, A., Morimura, H., Miki, A., Tano, Y. Brain Res. (2003) [Pubmed]
  26. Study of drug effects of calcium channel blockers on retinal degeneration of rd mouse. Takano, Y., Ohguro, H., Dezawa, M., Ishikawa, H., Yamazaki, H., Ohguro, I., Mamiya, K., Metoki, T., Ishikawa, F., Nakazawa, M. Biochem. Biophys. Res. Commun. (2004) [Pubmed]
  27. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Niwa, T., Shiraga, T., Hashimoto, T., Kagayama, A. Biol. Pharm. Bull. (2004) [Pubmed]
  28. Carbamazepine decreases antihypertensive effect of nilvadipine. Yasui-Furukori, N., Tateishi, T. Journal of clinical pharmacology. (2002) [Pubmed]
  29. Effects of nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension. Kagawa, H., Nomura, S., Ozaki, Y., Nagahama, M., Fukuhara, S. Clin. Exp. Hypertens. (1999) [Pubmed]
  30. Therapeutic effects of nilvadipine on rat focal cerebral ischemia. Li, Y., Kawamura, S., Yasui, N., Shirasawa, M., Fukasawa, H. Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale. (1994) [Pubmed]
  31. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Paris, D., Quadros, A., Humphrey, J., Patel, N., Crescentini, R., Crawford, F., Mullan, M. Brain Res. (2004) [Pubmed]
  32. Determination of the unbound concentration of hydrophobic drugs in albumin solutions by high-performance frontal analysis using a diol-silica column. Shibukawa, A., Nakao, C., Sawada, T., Terakita, A., Morokoshi, N., Nakagawa, T. Journal of pharmaceutical sciences. (1994) [Pubmed]
WikiGenes - Universities